Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment?

Journal of Clinical Psychiatry

Volumn 69, Issue 4, 2008, Pages 674-675

  Correll, Christoph U ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; QUETIAPINE;

AGITATION; ANXIETY; ANXIETY DISORDER; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; LOW DRUG DOSE; MONOTHERAPY; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SHORT SURVEY; SIDE EFFECT; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 44849087549     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0422     Document Type: Short Survey

References (11)

1. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991;17(2):217-245
2. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005;(2):CD000076
3. Correll CU. Antipsychotic polypharmacy: risks and benefits. CNS Drugs. In press
4. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007 Jan;89(1-3):91-100
5. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002;28(1):17-29
6. Leslie DL, Rosenheck RA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 2001 Sep;39(9):923-933
7. Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry 2004 Feb;161(suppl 2):1-56
8. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 Sep;45(9):789-796
9. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006 Oct;32(4):715-723
10. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006 Apr;163(4):600-610
11. Freudenreich O, Goff DC. Polypharmacy in schizophrenia: a fuzzy concept [letter]. J Clin Psychiatry 2003 Sep;64(9):1132